CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

Inclusion Criteria

• •Patient must be ≥ 18 years of age.
• •Histologically proven prostate adenocarcinoma
• •* Gleason score 2-10 (reviewed by reference lab)
• •* Biopsy within one year of date of registration
• •* Clinical stage T1b-T4, N0-Nx, M0-Mx (AJCC 7th Edition)
• •* T-stage and N-stage determined by physical exam and available imaging studies (ultrasound, CT, and/or MRI; see section 4.5)
• •* M-stage determined by physical exam, CT or MRI. Bone scan not required unless clinical findings suggest possible osseous metastases.
• •PSA ≤ 50 ng/ml, CBC, platelets, BUN, creatinine prior to treatment
• •Patients belonging in one of the following risk groups:
• •* Intermediate: CS T2b-c and Gleason \<6 and PSA ≤ 10, or CS T1b-T2b, and Gleason 7 and PSA ≤ 10 ng/ml, or Gleason \<6 and PSA 11-20 ng/ml
• •* High: CS T3-4, Gleason score \>7and PSA\<50
• •Prostate volume: ≤ 100 cc
• •* Determined using: volume = π/6 x length x height x width
• •* Measurement from MRI, CT or ultrasound prior to registration.
• •ECOG performance status 0-1
• •No prior prostatectomy or cryotherapy of the prostate
• •No prior radiotherapy to the prostate or lower pelvis
• •No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion.
• •No chemotherapy for a malignancy in the last 5 years.
• •No history of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years.